Indian firm to produce oseltamivir for developing countriesBMJ 2006; 332 doi: http://dx.doi.org/10.1136/bmj.332.7532.5-a (Published 05 January 2006) Cite this as: BMJ 2006;332:5
- Ganapati Mudur
- New Delhi
Roche has granted India's Hetero Drugs a sublicense for the production of the antiviral drug oseltamivir (Tamiflu) to accelerate the international stockpiling of the drug as part of influenza pandemic preparedness.
It said that the agreement would enhance supply of oseltamivir to developing countries “earlier than anticipated” and create capacity for future orders. Hetero, which is based in Hyderabad, will be able to sell oseltamivir in India …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial